Dermata Therapeutics Inc.
Dermata Therapeutics Inc. (DRMA): 3 pipeline candidates · ~8 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.4 months
D/E 0.16 · 0% dilution
Lead: Phase 3
3 candidates
N/A
1 buy · 0 sells (180d)
A transparent, data-derived signal for Dermata Therapeutics Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$5.5M
Cash
$6.9M
Quarterly Burn
$2.5M
Runway
8.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$83K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 48,334 | $58K |
| welch & forbes llc | 20,000 | $24K |
| citigroup inc | 1 | $1 |
Frequently asked questions
How many drug candidates are in Dermata Therapeutics Inc.'s pipeline?
Dermata Therapeutics Inc. (DRMA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Dermata Therapeutics Inc.'s lead drug candidate?
Dermata Therapeutics Inc.'s most advanced tracked candidate is DMT310 (Phase 3) for Acne Vulgaris.
What is Dermata Therapeutics Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Dermata Therapeutics Inc. has approximately 8.4 months of cash runway.
What is Dermata Therapeutics Inc.'s market capitalization?
Dermata Therapeutics Inc.'s market capitalization is approximately $5.5M.
Who is the CEO of Dermata Therapeutics Inc.?
Mr. Gerald T. Proehl is the chief executive officer of Dermata Therapeutics Inc. (DRMA).
Get the full picture on Dermata Therapeutics Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.